Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2004 2
2005 2
2006 4
2007 5
2008 1
2009 1
2011 1
2014 1
2015 2
2016 1
2017 3
2018 7
2019 1
2020 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Results by year

Filters applied: . Clear all
Page 1
Discovery of fluorobenzimidazole HCV NS5A inhibitors.
Randolph JT, Flentge CA, Donner P, Rockway TW, Patel SV, Nelson L, Hutchinson DK, Mondal R, Mistry N, Reisch T, Dekhtyar T, Krishnan P, Pilot-Matias T, Stolarik DF, Beno DWA, Wagner R, Maring C, Kati WM. Randolph JT, et al. Among authors: dekhtyar t. Bioorg Med Chem Lett. 2016 Nov 15;26(22):5462-5467. doi: 10.1016/j.bmcl.2016.10.030. Epub 2016 Oct 13. Bioorg Med Chem Lett. 2016. PMID: 27780635
Synthesis and evaluation of 2'-dihalo ribonucleotide prodrugs with activity against hepatitis C virus.
Chris Krueger A, Chen HJ, Randolph JT, Brown BS, Halvorsen GT, Heyman HR, Li T, Marvin CC, Shanley JP, Voight EA, Bow DAJ, Van Handel C, Peterkin V, Carr RA, Stolarik D, Dekhtyar T, Irvin ML, Krishnan P, Henry RF, Wagner R, DeGoey DA. Chris Krueger A, et al. Among authors: dekhtyar t. Bioorg Med Chem. 2020 Jan 1;28(1):115208. doi: 10.1016/j.bmc.2019.115208. Epub 2019 Nov 11. Bioorg Med Chem. 2020. PMID: 31740203
Discovery of 2-aminoisobutyric acid ethyl ester (AIBEE) phosphoramidate prodrugs for delivering nucleoside HCV NS5B polymerase inhibitors.
Randolph JT, Li T, Chris Krueger A, Heyman HR, Chen HJ, Bow DAJ, Van Handel C, Peterkin V, Carr RA, Stolarik D, Dekhtyar T, Irvin M, Krishnan P, Wagner R, DeGoey DA. Randolph JT, et al. Among authors: dekhtyar t. Bioorg Med Chem Lett. 2020 Apr 1;30(7):126986. doi: 10.1016/j.bmcl.2020.126986. Epub 2020 Jan 25. Bioorg Med Chem Lett. 2020. PMID: 32046903
Resistance characterization of hepatitis C virus genotype 2 from Japanese patients treated with ombitasvir and paritaprevir/ritonavir.
Schnell G, Tripathi R, Krishnan P, Beyer J, Reisch T, Irvin M, Dekhtyar T, Setze C, Rodrigues L Jr, Alves K, Burroughs M, Redman R, Chayama K, Kumada H, Collins C, Pilot-Matias T. Schnell G, et al. Among authors: dekhtyar t. J Med Virol. 2018 Jan;90(1):109-119. doi: 10.1002/jmv.24923. Epub 2017 Sep 22. J Med Virol. 2018. PMID: 28842997 Free PMC article. Clinical Trial.
Integrated Resistance Analysis of CERTAIN-1 and CERTAIN-2 Studies in Hepatitis C Virus-Infected Patients Receiving Glecaprevir and Pibrentasvir in Japan.
Krishnan P, Schnell G, Tripathi R, Beyer J, Reisch T, Dekhtyar T, Irvin M, Xie W, Fu B, Burroughs M, Redman R, Kumada H, Chayama K, Collins C, Pilot-Matias T. Krishnan P, et al. Among authors: dekhtyar t. Antimicrob Agents Chemother. 2018 Jan 25;62(2):e02217-17. doi: 10.1128/AAC.02217-17. Print 2018 Feb. Antimicrob Agents Chemother. 2018. PMID: 29180522 Free PMC article. Clinical Trial.
In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS3/4A Protease Inhibitor Glecaprevir.
Ng TI, Tripathi R, Reisch T, Lu L, Middleton T, Hopkins TA, Pithawalla R, Irvin M, Dekhtyar T, Krishnan P, Schnell G, Beyer J, McDaniel KF, Ma J, Wang G, Jiang LJ, Or YS, Kempf D, Pilot-Matias T, Collins C. Ng TI, et al. Among authors: dekhtyar t. Antimicrob Agents Chemother. 2017 Dec 21;62(1):e01620-17. doi: 10.1128/AAC.01620-17. Print 2018 Jan. Antimicrob Agents Chemother. 2017. PMID: 29084747 Free PMC article.
Pooled Resistance Analysis in Patients with Hepatitis C Virus Genotype 1 to 6 Infection Treated with Glecaprevir-Pibrentasvir in Phase 2 and 3 Clinical Trials.
Krishnan P, Pilot-Matias T, Schnell G, Tripathi R, Ng TI, Reisch T, Beyer J, Dekhtyar T, Irvin M, Xie W, Larsen L, Mensa FJ, Collins C. Krishnan P, et al. Among authors: dekhtyar t. Antimicrob Agents Chemother. 2018 Sep 24;62(10):e01249-18. doi: 10.1128/AAC.01249-18. Print 2018 Oct. Antimicrob Agents Chemother. 2018. PMID: 30061289 Free PMC article. Clinical Trial.
Resistance Analysis of a 3-Day Monotherapy Study with Glecaprevir or Pibrentasvir in Patients with Chronic Hepatitis C Virus Genotype 1 Infection.
Ng TI, Pilot-Matias T, Tripathi R, Schnell G, Krishnan P, Reisch T, Beyer J, Dekhtyar T, Irvin M, Lu L, Asatryan A, Campbell A, Yao B, Lovell S, Mensa F, Lawitz EJ, Kort J, Collins C. Ng TI, et al. Among authors: dekhtyar t. Viruses. 2018 Aug 28;10(9):462. doi: 10.3390/v10090462. Viruses. 2018. PMID: 30154359 Free PMC article. Clinical Trial.
Highlights of the Structure-Activity Relationships of Benzimidazole Linked Pyrrolidines Leading to the Discovery of the Hepatitis C Virus NS5A Inhibitor Pibrentasvir (ABT-530).
Wagner R, Randolph JT, Patel SV, Nelson L, Matulenko MA, Keddy R, Pratt JK, Liu D, Krueger AC, Donner PL, Hutchinson DK, Flentge C, Betebenner D, Rockway T, Maring CJ, Ng TI, Krishnan P, Pilot-Matias T, Collins C, Panchal N, Reisch T, Dekhtyar T, Mondal R, Stolarik DF, Gao Y, Gao W, Beno DA, Kati WM. Wagner R, et al. Among authors: dekhtyar t. J Med Chem. 2018 May 10;61(9):4052-4066. doi: 10.1021/acs.jmedchem.8b00082. Epub 2018 Apr 23. J Med Chem. 2018. PMID: 29653491
29 results